{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T06:53:41Z","timestamp":1773384821111,"version":"3.50.1"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ibroneuroscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.neuroscience.2026.02.028","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:23:34Z","timestamp":1771287814000},"page":"162-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Hallucinogenic Therapy in Alzheimer\u2019s Disease targeting Mitochondria-Associated Membranes"],"prefix":"10.1016","volume":"599","author":[{"given":"Fernando","family":"Minauro-Sanmiguel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9907-7192","authenticated-orcid":false,"given":"Hector","family":"Vargas-Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2026.02.028_b0005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10571-016-0366-z","article-title":"Introduction to extracellular vesicles: biogenesis, RNA cargo selection, content, release, and uptake","volume":"36","author":"Abels","year":"2016","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0010","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/cpt.117","article-title":"Cannabinoids in late-onset Alzheimer\u2019s disease","volume":"97","author":"Ahmed","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0015","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1177\/1073858407303536","article-title":"Amyloid precursor protein and mitochondrial dysfunction in Alzheimer\u2019s disease","volume":"13","author":"Anandatheerthavarada","year":"2007","journal-title":"Neuroscientist"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1515\/revneuro.2007.18.5.343","article-title":"Mitochondrial translocation of amyloid precursor protein and its cleaved products: relevance to mitochondrial dysfunction in Alzheimer\u2019s disease","volume":"18","author":"Anandatheerthavarada","year":"2007","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0025","article-title":"Role of mtDNA disturbances in the pathogenesis of Alzheimer\u2019s and Parkinson's disease","volume":"91\u201392","author":"Antonyov\u00e1","year":"2020","journal-title":"DNA Repair (AMST)"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0030","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1096\/fj.201601309","article-title":"On the pathogenesis of Alzheimer\u2019s disease: the MAM hypothesis","volume":"31","author":"Area-Gomez","year":"2017","journal-title":"FASEB J."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0035","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00213-024-06599-5","article-title":"Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties","volume":"242","author":"Atiq","year":"2024","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0040","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11920-022-01363-y","article-title":"The emerging field of psychedelic psychotherapy","volume":"24","author":"Barber","year":"2022","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0045","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1176\/appi.ps.20220525","article-title":"Ethical and practical considerations for the use of psychedelics in psychiatry","volume":"74","author":"Barber","year":"2023","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0050","doi-asserted-by":"crossref","first-page":"610","DOI":"10.2174\/1567205013666151221145445","article-title":"Evidence for mitochondrial UPR gene activation in familial and sporadic Alzheimer\u2019s disease","volume":"13","author":"Beck","year":"2016","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0055","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005593","article-title":"Cholinesterase inhibitors for Alzheimer\u2019s disease","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst Rev 2006"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0060","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41386-025-02097-0","article-title":"Psilocybin therapy for mood dysfunction in Parkinson\u2019s disease: an open-label pilot trial","volume":"50","author":"Bradley","year":"2025","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0065","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.celrep.2018.12.051","article-title":"Choline is an intracellular messenger linking extracellular stimuli to IP3-evoked Ca2+ signals through sigma-1 receptors","volume":"26","author":"Brailoiu","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0070","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.mito.2021.02.014","article-title":"The diversity and coexistence of extracellular mitochondria in circulation: a friend or foe of the immune system","volume":"58","author":"Caicedo","year":"2021","journal-title":"Mitochondrion"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0075","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","article-title":"A non-hallucinogenic psychedelic analogue with therapeutic potential","volume":"589","author":"Cameron","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0080","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: past, present, and future","volume":"42","author":"Carhart-Harris","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0085","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnint.2013.00025","article-title":"Serotonin modulation of cortical neurons and networks","volume":"7","author":"Celada","year":"2013","journal-title":"Front. Integr. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0090","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s12264-014-1479-3","article-title":"Humanin attenuates Alzheimer-like cognitive deficits and pathological changes induced by amyloid \u03b2-peptide in rats","volume":"30","author":"Chai","year":"2014","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0095","first-page":"1","article-title":"N, N-Dimethyltryptamine, a natural hallucinogen, ameliorates Alzheimer\u2019s disease by restoring neuronal Sigma-1 receptor-mediated endoplasmic reticulum-mitochondria crosstalk","volume":"16","author":"Cheng","year":"2024","journal-title":"Alzheimer\u2019s Res. Therapy"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0100","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00011-024-01973-7","article-title":"Mitochondrial damage causes inflammation via cGAS-STING signaling in ketamine-induced cystitis","volume":"74","author":"Chen","year":"2025","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-12816-z","article-title":"Regulation of the ER stress response by a mitochondrial microprotein","volume":"10","author":"Chu","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0110","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s11357-020-00287-w","article-title":"Disease-specific plasma levels of mitokines FGF21, GDF15, and Humanin in type II diabetes and Alzheimer\u2019s disease in comparison with healthy aging","volume":"43","author":"Conte","year":"2021","journal-title":"Geroscience"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0115","article-title":"Safety and efficacy of memantine extended-release in the management of Alzheimer\u2019s disease","volume":"5","author":"Corbett","year":"2013","journal-title":"Clin Med Insights Ther"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0120","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1471-4159.2005.03107.x","article-title":"5-HT receptors couple to activation of Akt, but not extracellular-regulated kinase (ERK), in cultured hippocampal neurons","volume":"93","author":"Cowen","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0125","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1093\/hmg\/ddq160","article-title":"Molecular mechanisms of neurodegeneration in Alzheimer\u2019s disease","volume":"19","author":"Crews","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2025.111278","article-title":"Psychedelics in neuroinflammation: mechanisms and therapeutic potential","volume":"137","author":"de Deus","year":"2025","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0135","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0140","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1021\/bi1013744","article-title":"A kinetic aggregation assay allowing selective and sensitive amyloid-\u03b2 quantification in cells and tissues","volume":"50","author":"Du","year":"2011","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0145","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249521","article-title":"Molecular dysfunctions of mitochondria-associated membranes (MAMs) in Alzheimer\u2019s disease","volume":"21","author":"Eysert","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0150","doi-asserted-by":"crossref","first-page":"11028","DOI":"10.1073\/pnas.1821332116","article-title":"Serotonin regulates mitochondrial biogenesis and function in rodent cortical neurons via the 5-HT2A receptor and SIRT1-PGC-1\u03b1 axis","volume":"116","author":"Fanibunda","year":"2019","journal-title":"PNAS"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-016-0112-5","article-title":"Redundant Gs-coupled serotonin receptors regulate amyloid-\u03b2 metabolism in vivo","volume":"11","author":"Fisher","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0160","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/02698811231164707","article-title":"Effects of serotonergic psychedelics on mitochondria: transdiagnostic implications for mitochondria-related pathologies","volume":"37","author":"Fissler","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0165","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1126\/science.1166127","article-title":"The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator","volume":"323","author":"Fontanilla","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0170","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41583-021-00533-w","article-title":"The probabilistic model of Alzheimer disease: the amyloid hypothesis revised","volume":"23","author":"Frisoni","year":"2022","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-024-49894-7","article-title":"Insight into binding of endogenous neurosteroid ligands to the sigma-1 receptor","volume":"15","author":"Fu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0180","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2174\/1567205014666170417111859","article-title":"Tau in Alzheimer\u2019s disease: mechanisms and therapeutic strategies","volume":"15","author":"Gao","year":"2018","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0185","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/7854_2021_267","article-title":"Psychedelics as novel therapeutics in Alzheimer\u2019s disease: rationale and potential mechanisms","author":"Garcia-Romeu","year":"2021","journal-title":"Disruptive Psychopharmacology"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0190","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1111\/jnc.16017","article-title":"Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: a systematic review","volume":"168","author":"Gattuso","year":"2024","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0195","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/MLR.0b013e31818457ce","article-title":"Predictors of nursing home admission for persons with dementia","volume":"47","author":"Gaugler","year":"2009","journal-title":"Med. Care"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0200","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1089\/jpm.2022.0604","article-title":"Exploring the potential utility of psychedelic therapy for patients with amyotrophic lateral sclerosis","volume":"26","author":"Gold","year":"2023","journal-title":"J. Palliat. Med."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0205","doi-asserted-by":"crossref","first-page":"8439","DOI":"10.1523\/JNEUROSCI.1121-22.2022","article-title":"Psychedelics and neural plasticity: therapeutic implications","volume":"42","author":"Grieco","year":"2022","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0210","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70491","article-title":"Donanemab exposure-response in early symptomatic Alzheimer\u2019s disease","volume":"21","author":"Gueorguieva","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0215","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0220","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ceb.2020.02.010","article-title":"The multifunctional nature of mitochondrial contact site proteins","volume":"65","author":"Harper","year":"2020","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0225","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2007.08.036","article-title":"Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival","volume":"131","author":"Hayashi","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0230","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1517\/14728222.2011.560837","article-title":"Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders","volume":"15","author":"Hayashi","year":"2011","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0235","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1242\/jcs.075119","article-title":"The mitochondrial UPR - protecting organelle protein homeostasis","volume":"123","author":"Haynes","year":"2010","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0240","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/nn.4017","article-title":"The case for rejecting the amyloid cascade hypothesis","volume":"18","author":"Herrup","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0245","unstructured":"Johns Hopkins University (2021\u20132025) Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer\u2019s Disease. In: ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04123314. Jun 2025."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0250","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2019","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0255","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0260","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00401-020-02196-w","article-title":"The physiological roles of tau and A\u03b2: implications for Alzheimer\u2019s disease pathology and therapeutics","volume":"140","author":"Kent","year":"2020","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0265","article-title":"Psychedelic drugs in mental disorders: current clinical scope and deep learning-based advanced perspectives","volume":"12","author":"Kim","year":"2025","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0270","article-title":"Psychedelics, mystical experience, and therapeutic efficacy: a systematic review","volume":"13","author":"Ko","year":"2022","journal-title":"Front. Psych."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0275","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2210599120","article-title":"Small mitochondrial protein NERCLIN regulates cardiolipin homeostasis and mitochondrial ultrastructure","volume":"120","author":"Konovalova","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0280","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cell.2012.12.004","article-title":"Dynamic interaction between sigma-1 receptor and Kv1.2 shapes neuronal and behavioral responses to cocaine","volume":"152","author":"Kourrich","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2025.106117","article-title":"Insights on psychedelics: a systematic review of therapeutic effects","volume":"173","author":"Kugel","year":"2025","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0290","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.molcel.2023.02.016","article-title":"Metabolic sensing and control in mitochondria","volume":"83","author":"Liu","year":"2023","journal-title":"Mol. Cell"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0295","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JAD-141959","article-title":"A phase II trial of tideglusib in Alzheimer\u2019s disease","volume":"45","author":"Lovestone","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2024.111139","article-title":"The immunomodulatory effects of classical psychedelics: a systematic review of preclinical studies","volume":"136","author":"Low","year":"2025","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0305","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1126\/science.1091230","article-title":"ABAD directly links A\u00df to mitochondrial toxicity in Alzheimer\u2019s disease","volume":"304","author":"Lustbader","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0310","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0315","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jalz.2011.05.2410","article-title":"Neuropsychiatric symptoms in Alzheimer\u2019s disease","volume":"7","author":"Lyketsos","year":"2011","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0320","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41401-023-01201-8","article-title":"Sigma-1 receptor activation mediates the sustained antidepressant effect of ketamine in mice via increasing BDNF levels","volume":"45","author":"Ma","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0325","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbi.2023.09.004","article-title":"Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: an experimental, placebo-controlled study","volume":"114","author":"Mason","year":"2023","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0330","doi-asserted-by":"crossref","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","article-title":"Alzheimer\u2019s disease","volume":"1","author":"Masters","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 2","key":"10.1016\/j.neuroscience.2026.02.028_b0335","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3233\/JAD-2011-102076","article-title":"Humanin signal for Alzheimer\u2019s disease","volume":"24","author":"Matsuoka","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0340","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1527-3458.2006.00113.x","article-title":"Humanin and colivelin: neuronal-death-suppressing peptides for Alzheimer\u2019s disease and amyotrophic lateral sclerosis","volume":"12","author":"Matsuoka","year":"2006","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0345","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharmthera.2009.07.001","article-title":"The pharmacology of sigma-1 receptors","volume":"124","author":"Maurice","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0350","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2025.1455902","article-title":"The phenomenology of psilocybin: transformative insights for research and clinical practice","volume":"16","author":"Metastasio","year":"2025","journal-title":"Front. Psychol."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0355","doi-asserted-by":"crossref","DOI":"10.1172\/JCI158449","article-title":"Mitochondria-derived peptides in aging and healthspan","author":"Miller","year":"2022","journal-title":"J Clin Invest 132."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0360","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/s41380-023-01956-w","article-title":"Mitochondrial DNA variation in Alzheimer\u2019s disease reveals a unique microprotein called SHMOOSE","volume":"28","author":"Miller","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0365","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1126\/science.1223560","article-title":"Mitochondrial import efficiency of ATFS-1 regulates mitochondrial UPR activation","volume":"337","author":"Nargund","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0370","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neulet.2019.04.022","article-title":"The complexity of tau in Alzheimer\u2019s disease","volume":"705","author":"Naseri","year":"2019","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0375","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.18632\/aging.204074","article-title":"Effect of Humanin G (HNG) on inflammation in age-related macular degeneration (AMD)","volume":"14","author":"Nashine","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0380","doi-asserted-by":"crossref","first-page":"C670","DOI":"10.1152\/ajpcell.00213.2006","article-title":"The mitochondrial energy transduction system and the aging process","volume":"292","author":"Navarro","year":"2007","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0385","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jphs.2014.12.005","article-title":"Role of sigma-1 receptors in neurodegenerative diseases","volume":"127","author":"Nguyen","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2021.130024","article-title":"Humanin and Alzheimer\u2019s disease: the beginning of a new field","volume":"1866","author":"Niikura","year":"2022","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2024.111155","article-title":"Comparing psilocybin to metformin as neuroprotective agents against Parkinson\u2019s dementia: a systematic review of evidence and efficacy","volume":"136","author":"Ordovich-Clarkson","year":"2025","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0400","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1128\/MCB.01337-13","article-title":"SirT3 regulates the mitochondrial unfolded protein response","volume":"34","author":"Papa","year":"2014","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0405","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.cmet.2022.10.008","article-title":"Mitochondrial signal transduction","volume":"34","author":"Picard","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0410","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241813835","article-title":"Mitochondrial-Derived Vesicles: the good, the bad, and the Ugly","volume":"24","author":"Picca","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0415","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512513","article-title":"A Brief Review on the potential of Psychedelics for Treating Alzheimer\u2019s Disease and Related Depression","volume":"24","author":"Pilozzi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0420","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ana.23955","article-title":"Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease","volume":"74","author":"Podlesniy","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0425","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.cellsig.2011.09.009","article-title":"Functional significance of glycogen synthase kinase-3 regulation by serotonin","volume":"24","author":"Polter","year":"2012","journal-title":"Cell. Signal."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0430","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.pscychresns.2011.06.014","article-title":"Amygdala atrophy is prominent in early Alzheimer\u2019s disease and relates to symptom severity","volume":"194","author":"Poulin","year":"2011","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0435","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1124\/jpet.109.159947","article-title":"5-hydroxytryptamine receptor stimulation of mitochondrial biogenesis","volume":"332","author":"Rasbach","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0440","doi-asserted-by":"crossref","unstructured":"Reiff, C.M., Richman, E.E., Nemeroff, C.B., et al, 2021. Psychedelics and psychedelic-assisted psychotherapy. Focus (Am Psychiatr Publ) 19:95\u2013115.","DOI":"10.1176\/appi.focus.19104"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0445","doi-asserted-by":"crossref","unstructured":"Reisberg, B., Doody, R., St\u00f6ffler, A., et al., 2003. Memantine in Moderate-to-Severe Alzheimer\u2019s Disease. https:\/\/doi.org\/10.1056\/NEJMoa013128.","DOI":"10.1056\/NEJMoa013128"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0450","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X15666170116143743","article-title":"the Amyloid cascade hypothesis in Alzheimer\u2019s disease: It's time to change our mind","volume":"15","author":"Ricciarelli","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0455","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mam.2015.05.005","article-title":"Neuropsychiatric symptoms in Alzheimer\u2019s disease: what might be associated brain circuits?","volume":"43\u201344","author":"Rosenberg","year":"2015","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0460","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/brain\/awaa376","article-title":"Alzheimer\u2019s disease brain-derived extracellular vesicles spread tau pathology in interneurons","volume":"144","author":"Ruan","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0465","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/jnc.15544","article-title":"Psychedelic-inspired approaches for treating neurodegenerative disorders","volume":"162","author":"Saeger","year":"2022","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0470","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","article-title":"Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo","volume":"109","author":"Shao","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0475","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.685201","article-title":"Sigma-1 receptor: a potential therapeutic target for traumatic brain injury","volume":"15","author":"Shi","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0480","doi-asserted-by":"crossref","unstructured":"Sinha, J.K., Ghosh, S,. Singh, K.K., et al., 2024a. Exploring therapeutic potentials and pathways of psychedelics in Alzheimer\u2019s disease\u2010related dementia. Alzheimers Dement 20.: https:\/\/doi.org\/10.1002\/alz.084413.","DOI":"10.1002\/alz.084413"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102211","article-title":"Psychedelics for alzheimer\u2019s disease-related dementia: Unveiling therapeutic possibilities and pathways","volume":"96","author":"Sinha","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0490","unstructured":"Smith, G.S., 2015. Handbook of Depression in Alzheimer\u2019s Disease. IOS Press."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0495","doi-asserted-by":"crossref","unstructured":"Smith, S.B., Su, T.-P. (eds), 2018. Sigma receptors: Their role in disease and as therapeutic targets. Springer International Publishing, Cham, Switzerland.","DOI":"10.1007\/978-3-319-50174-1_1"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0500","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41556-018-0124-1","article-title":"The multifaceted contributions of mitochondria to cellular metabolism","volume":"20","author":"Spinelli","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0505","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1016\/j.celrep.2018.06.002","article-title":"Mitoregulin: a lncRNA-encoded microprotein that supports mitochondrial supercomplexes and respiratory efficiency","volume":"23","author":"Stein","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0510","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3390\/rel16070893","article-title":"Shamanic imagery and ritual experience: an empirical study of emotions, beliefs, and states of consciousness","volume":"16","author":"Sun","year":"2025","journal-title":"Religions"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0515","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.tips.2010.08.007","article-title":"The sigma-1 receptor chaperone as an inter-organelle signaling modulator","volume":"31","author":"Su","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0520","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.tips.2016.01.003","article-title":"The sigma-1 receptor as a pluripotent modulator in living systems","volume":"37","author":"Su","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0525","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3233\/JAD-170585","article-title":"Mitochondria and mitochondrial cascades in Alzheimer\u2019s disease","volume":"62","author":"Swerdlow","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0530","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/bs.irn.2020.01.008","article-title":"The mitochondrial hypothesis: dysfunction, bioenergetic defects, and the metabolic link to Alzheimer\u2019s disease","volume":"154","author":"Swerdlow","year":"2020","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0535","first-page":"347","article-title":"Pathogenesis of Alzheimer\u2019s disease","volume":"2","author":"Swerdlow","year":"2007","journal-title":"Clin. Interv. Aging"},{"issue":"Suppl 2","key":"10.1016\/j.neuroscience.2026.02.028_b0540","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.3233\/JAD-2010-100339","article-title":"The Alzheimer\u2019s disease mitochondrial cascade hypothesis","volume":"20","author":"Swerdlow","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0545","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1212\/WNL.0b013e318245f48d","article-title":"Alzheimer disease: can the exam predict the pathology?","volume":"78","author":"Swerdlow","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0550","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00358","article-title":"Psychedelics and immunomodulation: novel approaches and therapeutic opportunities","volume":"6","author":"Szabo","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106533","article-title":"Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells","volume":"9","author":"Szabo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0560","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13041-019-0447-2","article-title":"The secreted APP ectodomain sAPP\u03b1, but not sAPP\u03b2, protects neurons against A\u03b2 oligomer-induced dendritic spine loss and increased tau phosphorylation","volume":"12","author":"Tackenberg","year":"2019","journal-title":"Mol. Brain"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0565","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s11064-022-03772-0","article-title":"The missing piece? a case for microglia\u2019s prominent role in the therapeutic action of anesthetics, ketamine, and psychedelics","volume":"48","author":"VanderZwaag","year":"2023","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0570","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/02791072.2022.2033889","article-title":"Neural plasticity in the ventral tegmental area, aversive motivation during drug withdrawal and hallucinogenic therapy","volume":"55","author":"Vargas-Perez","year":"2023","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.neuroscience.2026.02.028_b0575","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","article-title":"Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders","volume":"21","author":"Vollenweider","year":"2020","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0580","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3390\/psychoactives3030026","article-title":"\u201cMind-revealing\u201d psychedelic states: psychological processes in subjective experiences that drive positive change","volume":"3","author":"Walther","year":"2024","journal-title":"Psychoactives"},{"issue":"1","key":"10.1016\/j.neuroscience.2026.02.028_bib641","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13024-020-00376-6","article-title":"Mitochondria dysfunction in the pathogenesis of Alzheimer\u2019s disease: recent advances","volume":"15","author":"Wang","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-017-0380-6","article-title":"Roles of sigma-1 receptors on mitochondrial functions relevant to neurodegenerative diseases","volume":"24","author":"Weng","year":"2017","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0590","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1042\/BST20220518","article-title":"Interactions between amyloid, amyloid precursor protein, and mitochondria","volume":"51","author":"Wilkins","year":"2023","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0595","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3389\/fimmu.2017.00508","article-title":"Mitochondria-Derived Damage-Associated Molecular patterns in Neurodegeneration","volume":"8","author":"Wilkins","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0600","unstructured":"Wolfe, M.S., 2016. Developing Therapeutics for Alzheimer\u2019s Disease: Progress and Challenges. Academic Press."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0605","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.tcb.2021.10.010","article-title":"The dark proteome: translation from noncanonical open reading frames","volume":"32","author":"Wright","year":"2022","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0610","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bbrc.2019.09.094","article-title":"Altered mitochondrial DNA methylation and mitochondrial DNA copy number in an APP\/PS1 transgenic mouse model of Alzheimer disease","volume":"520","author":"Xu","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0615","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.1035746","article-title":"Altered anterior cingulate cortex subregional connectivity associated with cognitions for distinguishing the spectrum of pre-clinical Alzheimer\u2019s disease","volume":"14","author":"Yuan","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0620","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/jnc.15260","article-title":"Pimavanserin, a 5HT2A receptor inverse agonist, rapidly suppresses a\u03b2 production and related pathology in a mouse model of Alzheimer\u2019s disease","volume":"156","author":"Yuede","year":"2021","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0625","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1042\/CS20200844","article-title":"Mitochondria-associated membranes (MAMs): a potential therapeutic target for treating Alzheimer\u2019s disease","volume":"135","author":"Yu","year":"2021","journal-title":"Clin. Sci. (Lond.)"},{"issue":"Suppl 1","key":"10.1016\/j.neuroscience.2026.02.028_b0630","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1471-4159.2011.07519.x","article-title":"Proteolytic processing of Alzheimer\u2019s \u03b2-amyloid precursor protein","volume":"120","author":"Zhang","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0635","first-page":"1","article-title":"Mitochondrial peptide BRAWNIN is essential for vertebrate respiratory complex III assembly","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuroscience.2026.02.028_b0640","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s11064-012-0951-6","article-title":"Neuroprotective Peptide humanin inhibits inflammatory response in astrocytes induced by lipopolysaccharide","volume":"38","author":"Zhao","year":"2013","journal-title":"Neurochem. Res."}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226001259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226001259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T01:28:10Z","timestamp":1773365290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452226001259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":129,"alternative-id":["S0306452226001259"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.02.028","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hallucinogenic Therapy in Alzheimer\u2019s Disease targeting Mitochondria-Associated Membranes","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.02.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Brain Research Organization (IBRO). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}